OBJECTIVES: (1) To describe the prevalence, timing and setting of documented end-of-life (EOL) discussions in patients with advanced ovarian cancer; and (2) to assess the impact of timing and setting of documented end-of-life discussions on EOL quality care measures. METHODS: A retrospective study of women who died of ovarian cancer diagnosed between 1999 and 2008 was conducted. The following are the EOL quality measures assessed: chemotherapy in the last 14 days of life, >1 hospitalization in the last 30 days, >1 ER visit in the last 30 days, intensive care unit (ICU) admission in the last 30 days, dying in an acute care setting, admitted to hospice ≤3 days. RESULTS: One hundred seventy-seven (80%) patients had documented end-of-life discussions. Median interval from EOL discussion until death was 29 days. Seventy-eight patients (44%) had EOL discussions as outpatient and 99 (56%) as inpatient. Sixty-four out of 220 (29%) patients' care did not conform to at least one EOL quality measure. An EOL discussion at least 30 days before death was associated with a lower incidence of: chemotherapy in the last 14 days of life (p=0.003), >1 hospitalization in the last 30 days (p<0.001), ICU admission in the last 30 days (p=0.005), dying in acute care setting (p=0.01), admitted to hospice ≤3 days (p=0.02). EOL discussion as outpatient was associated with fewer patients hospitalized >1 in the last 30days of life (p<0.001). CONCLUSIONS: End-of-life care discussions are occurring too late in the disease process. Conformance with EOL quality measures can be achieved with earlier end-of-life care discussions.
OBJECTIVES: (1) To describe the prevalence, timing and setting of documented end-of-life (EOL) discussions in patients with advanced ovarian cancer; and (2) to assess the impact of timing and setting of documented end-of-life discussions on EOL quality care measures. METHODS: A retrospective study of women who died of ovarian cancer diagnosed between 1999 and 2008 was conducted. The following are the EOL quality measures assessed: chemotherapy in the last 14 days of life, >1 hospitalization in the last 30 days, >1 ER visit in the last 30 days, intensive care unit (ICU) admission in the last 30 days, dying in an acute care setting, admitted to hospice ≤3 days. RESULTS: One hundred seventy-seven (80%) patients had documented end-of-life discussions. Median interval from EOL discussion until death was 29 days. Seventy-eight patients (44%) had EOL discussions as outpatient and 99 (56%) as inpatient. Sixty-four out of 220 (29%) patients' care did not conform to at least one EOL quality measure. An EOL discussion at least 30 days before death was associated with a lower incidence of: chemotherapy in the last 14 days of life (p=0.003), >1 hospitalization in the last 30 days (p<0.001), ICU admission in the last 30 days (p=0.005), dying in acute care setting (p=0.01), admitted to hospice ≤3 days (p=0.02). EOL discussion as outpatient was associated with fewer patients hospitalized >1 in the last 30days of life (p<0.001). CONCLUSIONS: End-of-life care discussions are occurring too late in the disease process. Conformance with EOL quality measures can be achieved with earlier end-of-life care discussions.
Authors: Daniel Hong; Lauren C Das; Ellen Daily; Stacie K Levine; Olwen M Hahn; Stanley L Liauw; Daniel W Golden; Christina H Son Journal: Support Care Cancer Date: 2021-05-25 Impact factor: 3.603
Authors: Sangeeta C Ahluwalia; Diana M Tisnado; Anne M Walling; Sydney M Dy; Steven M Asch; Susan L Ettner; Benjamin Kim; Philip Pantoja; Hannah C Schreibeis-Baum; Karl A Lorenz Journal: J Palliat Med Date: 2015-07-17 Impact factor: 2.947
Authors: Gabrielle B Rocque; J Nicholas Dionne-Odom; Chao-Hui Sylvia Huang; Soumya J Niranjan; Courtney P Williams; Bradford E Jackson; Karina I Halilova; Kelly M Kenzik; Kerri S Bevis; Audrey S Wallace; Nedra Lisovicz; Richard A Taylor; Maria Pisu; Edward E Partridge; Thomas W Butler; Linda A Briggs; Elizabeth A Kvale Journal: J Pain Symptom Manage Date: 2017-01-03 Impact factor: 3.612
Authors: Lynn F Reinke; Laura C Feemster; Jennifer McDowell; Eric Gunnink; Erica V Tartaglione; Edmunds Udris; J Randall Curtis; David H Au Journal: Heart Lung Date: 2017 Jan - Feb Impact factor: 2.210
Authors: Alaina J Brown; Megan J Shen; Lois M Ramondetta; Diane C Bodurka; Robert L Giuntoli; Teresa Diaz-Montes Journal: Int J Gynecol Cancer Date: 2014-10 Impact factor: 3.437
Authors: William F Pirl; Joseph A Greer; Kelly Irwin; Inga T Lennes; Vicki A Jackson; Elyse R Park; Daisuke Fujisawa; Alexi A Wright; Jennifer S Temel Journal: J Oncol Pract Date: 2015-03-31 Impact factor: 3.840
Authors: Aluem Tark; Leah V Estrada; Mary E Tresgallo; Denise D Quigley; Patricia W Stone; Mansi Agarwal Journal: Palliat Med Date: 2020-03-10 Impact factor: 4.762